Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

224 FENTANYL
Exfoliative dermatitis
Fixed eruption
(2001): Vaughan K, Lakewood, WA (from patch) (from Internet)
(observation)
Papulo-nodular lesions (>1%)
Pruritus (3–44%)
(2006): Sarvela PJ+, Acta Anaesthesiol Scand 50(2), 239
(2002): Gurkan Y+, Anesth Analg 95(6), 1763
(2002): Henry A+, RegAnesthPainMed27(5), 538 (intrathecal)
(2002): Nelson KE+, Anesthesiology 96(5), 1070
(1999): Herman NL+, Anesth Analg 89, 378
(1996): Larijani GE+, Pharmacotherapy 16, 958
(1994): Gerwels JW+, JDermatolSurgOncol20, 823
(1992): Badner NH+, Can J Anaesth 39, 330
(1992): Belzarena SD, Anesth Analg 74, 653
(1992): Calis KA+, Clin Pharm 11, 22
(1992): Friesen RH+, Anesthesiology 76, 46 (facial)
(1992): Mosser KH, Am Fam Physician 45, 2289
(1992): Mourisse J+, Acta Anaesthesiol Scand 36, 70
(1992): Paech MJ, Anaesth Intensive Care 20, 15
(1992): Sandler ES+, Pediatrics 89, 631
(1992): Varrassi G+, Anaesthesia 47, 558
(1992): White MJ+, Can J Anaesth 39, 594
(1989): Ackerman WE+, Can J Anaesth 36, 388
(1989): Jorrot JC+, AnnFrAnesthRéanim(French) 8, 321 (22%)
(1988): Davies GG+, Anesthesiology 69, 763
(1988): Monk JP+, Drugs 36, 286 (40%)
(1986): Shipton EA+, SAfrMedJ70, 325 (13%)
Purpura
(2001): Tweed WA+, Anesth Analg 92, 1442
Pustules (1%)
(1992): Sandler ES+, Pediatrics 89, 631
(1992): Stoukides CA+, Clin Pharm 11, 222
Urticaria (10%)
(2001): Litt JZ, Beachwood, OH (personal case) (observation)
(1992): Calis KA+, Clin Pharm 11, 22
Other
Anaphylactoid reactions/Anaphylaxis
(2007): Cummings KC 3rd+, Can J Anaesth 54(4), 301
(2001): Girgis Y, Anaesthesia 56(10), 1016
(2001): Konarzewski W+, Anaesthesia 56(5), 497 (with
propofol) (fatal)
(2001): Lewis S+, Anaesthesia 56(11), 1128
(1990): Ducker P+, ZHautkr(German) 65, 734
Cough
(2007): Yeh CC+, J Clin Anesth 19(1), 53
(2006): Oshima T+, Can J Anaesth 53(8), 753
(2005): Schlimp CJ+, Can J Anaesth 52(2), 207
(2004): Pandey CK+, Anesth Analg 99(6), 1696
(2002): Tsou CH+, Acta Anaesthesiol Sin 40(4), 165
(2001): Tweed WA+, Anesth Analg 92(6), 1442
Death
(2005): Ekedahl A+, Lakartidningen 102(39), 2788
(2002): Mertes PM+, Anaesthesia 57(8), 821 (with propofol)
(2002): Reeves MD+, Med J Aust 177(10), 552
(2001): Girgis Y, Anaesthesia 56(10), 1016
Inappropriate secretion of antidiuretic hormone (SIADH)
(2002): Kokko H+, Pharmacotherapy 22(9), 1188
FEVERFEW
Scientific names: Chrysanthemum parthenium; Pyrethrum
parthenium; Tanacetum parthenium
Family: Asteraceae; Compositae
Trade and other common names: Atamisa; Featerfoiul;
Featherfew; Featherfoil; MIG-99; Santa Maria
Category: Antipyretic
Purported indications and other uses: Fever, headache,
migraine, menstrual irregularities, arthritis, psoriasis, allergy,
asthma, tinnitus, vertigo, nausea, cold, earache, orthopedic
disorders, swollen feet, diarrhea, dyspepsia
Half-life: N/A
Clinically important, potentially hazardous interactions
with: anticoagulants, NSAIDs, warfarin
Reactions
Skin
Adverse effects (sic) (mild)
(2000): Ernst E+, Public Health Nutr 3(4A), 509
Allergic reactions (sic)
(1983): Hausen BM+, Acta Derm Venereol 63(4), 308
Angioedema (lips)
(1998): Awang DVC, Int Med 1, 11
(1985): Johnson ES+, BMJ (Clin Res Ed) 291, 569
Dermatitis
(2006): Verma KK+, Indian J Dermatol Venereol Leprol 72(1), 24
(2002): Paulsen E+, Contact Dermatitis 47(1), 14
(1996): Lamminpaa A+, Contact Dermatitis 34, 330
Prurigo nodularis
(2000): Sharma VK+, Contact Dermatitis 42(4), 235
Mucosal
Oral ulceration
(1998): Awang DVC, Int Med 1, 11
(1985): Johnson ES+, BMJ (Clin Res Ed) 291, 569
FEXOFENADINE
Trade name: Allegra (Sanofi-Aventis)
Indications: Allergic rhinitis, pruritus, urticaria
Category: Histamine H1 receptor antagonist
Half-life: 14.4 hours
Clinically important, potentially hazardous interactions
with: St John’s wort
Reactions
Skin
Acne
(1998): Litt JZ, Beachwood, OH (personal case) (observation)
Psoriasis
(2006): Saraswat A+, Clin Exp Dermatol 31(3), 477 (Pustular)
Pustules
(2006): Saraswat A+, Clin Exp Dermatol 31(3), 477
FILGRASTIM
(See GRANULOCYTE COLONY-STIMULATING FACTOR
(GCSF))